发明名称 |
Duocarmycin ADCs for use in treatment of endometrial cancer |
摘要 |
The present invention relates to duocarmycin-containing antibody-drug conjugates (ADCs) for use in the treatment of human solid tumors expressing HER2, wherein the human solid tumor expressing HER2 is endometrial cancer, in particular uterine serous carcinoma (USC). In particular, the present invention relates to duocarmycin-containing ADCs for use in the treatment of endometrial cancer, notably USC, with HER2 IHC 2− or 1+ and HER2 FISH negative tumor tissue status. |
申请公布号 |
US9427480(B2) |
申请公布日期 |
2016.08.30 |
申请号 |
US201514859221 |
申请日期 |
2015.09.18 |
申请人 |
Synthon Biopharmaceuticals B.V.;Yale University |
发明人 |
Santin Alessandro Davide;Goedings Peter Johannes |
分类号 |
A61K47/48;A61K39/395;C07D405/12;A61K45/06;C07K16/40 |
主分类号 |
A61K47/48 |
代理机构 |
Sterne, Kessler, Goldstein & Fox P.L.L.C. |
代理人 |
Sterne, Kessler, Goldstein & Fox P.L.L.C. |
主权项 |
1. A method of treating uterine serous carcinoma expressing HER2 in a human patient, comprising administering to the patient a therapeutically effective amount of a compound having the structure wherein 2.5-2.9 represents an average DAR for the compound. |
地址 |
Nijmegen NL |